Inhibrx Biosciences Inc. (INBX) Stock Grade

About Inhibrx Biosciences Inc.'s fundamentals

Inhibrx Biosciences is a biotechnology company with a market capitalization of $1.5 billion that is experiencing dramatic revenue expansion, with year-over-year growth of 550%. However, the company reported a substantial net loss in its latest annual statement, reflected in a negative net margin of -10773.5%, indicating that expenses significantly exceed revenues. The company does not currently pay a dividend, and traditional profitability metrics like P/E ratio and return on equity are not applicable given its loss-making status.